Alzheimer's Disease Trial, Not Yet Recruiting NCT07573982 Sponsor: Stanford University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT07573982
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • A doctor has confirmed the person is amyloid-positive, based on a brain scan (amyloid PET), a past spinal fluid test, or a blood test measuring a protein called pTau-217.
  • The person is 18 years of age or older, of any gender, race, or ethnicity. Women under 60 will be asked about their menopause status and may need to take a urine pregnancy test to confirm they are not pregnant.
  • The person has no dementia, very mild dementia, or mild dementia, as measured by a standard rating scale (CDR score of 1.0 or lower).
  • The person is able and willing to attend six sessions of up to one hour each, sitting in a chair while an ultrasound device is placed on their scalp, plus additional time for brain scans, blood tests, and memory and thinking assessments.
  • The person is able to understand the study and is willing to sign a written consent form.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with moderate or severe dementia (CDR score above 1.0).
  • People who have brain tumours, active or past bleeding in the brain (beyond very small spots), or other significant brain conditions — a brain scan will be reviewed before enrolment to check for these (confirm with trial site).
  • People with another health condition that the treatment team believes would make the study results difficult to interpret, such as certain brain differences present from birth.
  • People with anything along the ultrasound path that could block or interfere with the sound waves, such as metal, air pockets, large calcium deposits in the skull, or hair or hair coverings (such as turbans, dreadlocks, or wigs/hairweaves) that cannot be removed for the sessions and that would prevent the device from making good contact with the scalp.
  • People who cannot have an MRI scan, whether due to claustrophobia, an unknown implanted device, or metal hardware in the head that would affect brain imaging.
  • People with an allergy or sensitivity to the materials used to attach the ultrasound device to the scalp, including ultrasound gel or silicone.
  • People who have received an anti-amyloid antibody treatment (a type of medication targeting amyloid in the brain) within the six months before screening.
  • People with moderate or more severe depression symptoms at the time of screening, based on a standard questionnaire score (PHQ-9 score of 10 or higher).
  • People with clinically significant thoughts of suicide or recent suicidal behaviour, as measured by a standard assessment tool.
  • People with significant abnormalities in their blood counts, including low red blood cell levels, low white blood cell levels, or low platelet levels (specific thresholds confirmed by trial site).
  • People with significant liver, kidney, lung, heart, or metabolic conditions that could increase the risk of harm or make results harder to interpret, including certain abnormal blood test results or a recent serious heart event within the past six months (confirm specific thresholds with trial site).
  • People with a significantly slow or fast heart rate (below 50 or above 100 beats per minute).
  • People with poorly controlled blood pressure.
  • People with uncontrolled diabetes, defined as a long-term blood sugar marker (HbA1c) above 7.5.
  • People with an active significant infection or other illness affecting the brain or nervous system.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

If you need support right now

This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.

If you or someone else is in immediate danger, call 000.

  • Lifeline — 24/7 crisis support: 13 11 14
  • Suicide Call Back Service — 24/7 counselling: 1300 659 467
  • 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
  • Beyond Blue — 24/7 mental health support: 1300 22 4636
  • Emergency: 000

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.

Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with Treatment-Related Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov